IP Library Granted Patent US 10,494,416
Granted Patent B2
US 10,494,416 · App. 15/595,733 · Granted Dec 3, 2019

Methods of modulating immune responses using BCMA polypeptide

Inventors: Jeffrey Browning (Brookline, MA); Christine Ambrose (Reading, MA); Fabienne MacKay (Vaucluse, AU); Jurg Tschopp (Epalinges, CH); Pascal Schneider (Epalinges, CH); Jeffrey Thompson (Stoneham, MA)
Assignees: Biogen MA Inc.; Topotarget Switzerland SA
C07K14/7151A61K38/17A61K39/395C07K14/70575C07K16/241A61K39/00A61K2039/505C07K2319/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,494,416
App. No.
15/595,733
Granted
Dec 3, 2019
Kind
B2
Abstract

A novel receptor in the TNF family is provided: BAFF-R. Chimeric molecules and antibodies to BAFF-R and methods of use thereof are also provided.

Claims (9)

1. A method of treating a B-cell lympho-proliferate disorder in a mammal, the method comprising the step of administering to the mammal an effective amount of a BCMA (B-Cell Maturation Antigen) polypeptide, wherein the BCMA polypeptide comprises an amino acid sequence that binds to BAFF (B-Cell Activating Factor of the TNF family; SEQ ID NO:9) and is:

a) at least 95% identical to amino acids 1-51 of SEQ ID NO:1; or

b) at least 95% identical to amino acids 8-41 of SEQ ID NO:1.

2. The method of claim 1 , wherein the BCMA polypeptide comprises an Fc domain of an immunoglobulin.

3. The method of claim 1 , wherein the mammal is human.

4. The method of claim 1 , wherein the BCMA polypeptide comprises the sequence of amino acids 1-51 of SEQ ID NO:1.

5. The method of claim 1 , wherein the BCMA polypeptide comprises the sequence of amino acids 8-41 of SEQ ID NO:1.

6. The method of claim 2 , wherein the immunoglobulin is IgG.

7. The method of claim 2 , wherein the immunoglobulin is human.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 8, 2017
From: TSCHOPP, JURG; SCHNEIDER, PASCAL
To: APOXIS, SA
Reel/Frame 044341/0207 →
CHANGE OF NAME Recorded Dec 8, 2017
From: BIOGEN IDEC MA INC.
To: BIOGEN MA INC.
Reel/Frame 044796/0054 →
MERGER AND CHANGE OF NAME Recorded Dec 8, 2017
From: APOXIS SA; TOPOTARGET SWITZERLAND SA
To: TOPOTARGET SWITZERLAND SA
Reel/Frame 044796/0260 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 8, 2017
From: THOMPSON, JEFFREY; AMBROSE, CHRISTINE; BROWNING, JEFFREY; MACKAY, FABIENNE
To: BIOGEN, INC.
Reel/Frame 044797/0673 →
CHANGE OF NAME Recorded Dec 8, 2017
From: BIOGEN, INC.
To: BIOGEN IDEC MA INC.
Reel/Frame 044803/0870 →
Continuity (9)
Division 14452870 · Aug 6, 2014
Continuation 13401610 · Feb 21, 2012
Continuation 12500909 · Jul 10, 2009
Continuation 10077137 · Feb 15, 2002
Continuation PCTUS0022507 · Aug 16, 2000
Provisional Application 60149378 · Aug 17, 1999
Provisional Application 60181684 · Feb 11, 2000
Provisional Application 60183536 · Feb 18, 2000
Related Publication 20180273605A1 · Sep 27, 2018
Cited By (2)
US 12,371,505 US 12,709,644